European Archives - Page 862 of 1214 - European Medical Journal

Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer

Surgery provides the best chance of a cure for patients with early stage non-small cell lung cancer (NSCLC) and plays an important role in the…

Innovating the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations: A Phone Telesystem to Increase Action Plan Adherence

Chronic obstructive pulmonary disease (COPD) exacerbations are major contributors to the burden of the disease, reducing patients’ quality of life…

Alternative Exercise and Breathing Interventions in Chronic Obstructive Pulmonary Disease: A Critical Review

Interventions such as exercise training and breathing strategies are components of pulmonary rehabilitation for people with chronic obstructive pulmonary…

Adherence Rate to Inhaled Therapies and Factors Affecting Adherence in Elderly Patients with Chronic Obstructive Lung Diseases

Adherence to treatment is essential in chronic diseases, especially in chronic obstructive lung diseases (COLD). Poor adherence to the treatment regimen…

This October 2018, EMJ Supports...

This October, EMJ has proudly showcased its support for Stoptober and World Psoriasis Day.

European Medical Journal Presents: EMJ Dermatology 6.1

The publication of EMJ Dermatology 6.1 is now available, containing a full review of the 27th European Academy of Dermatology and Venereology (EADV)…

Review of the European Academy of Dermatology and Venerology Congress 2018

Held in the city of Paris, France, on the 12th–16th September 2018, the 27th European Academy of Dermatology and Venereology (EADV) Congress lived up to…

EMJ Dermatology 6.1 2018

EMJ Dermatology 6.1 showcases fascinating content that will spark countless hours of intense debate, no doubt leading to further developments and…

Facial Lesions: A Dermoscopic Interactive Session

The differential diagnosis of pigmented macules on sun-damaged facial skin is one of the most challenging procedures in daily dermatological practice.

PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?

The main objectives of the symposium were to review recent evidence on what difference targeting Psoriasis Area Severity Index (PASI) 90 or 100 and…